Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Dapagliflozin"

26 News Found

Daewoong  completes combination therapy of antidiabetic drug Enavogliflozin
News | February 27, 2022

Daewoong completes combination therapy of antidiabetic drug Enavogliflozin

Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy


WHO new Essential Medicines Lists focus on diabetes and cancer
Public Health | September 30, 2021

WHO new Essential Medicines Lists focus on diabetes and cancer

The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all


Equipment shortage and overpriced APIs pinch the pharma industry
News | September 09, 2021

Equipment shortage and overpriced APIs pinch the pharma industry

A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges


Japan approves AstraZeneca’s Forxiga for chronic kidney disease
Drug Approval | August 28, 2021

Japan approves AstraZeneca’s Forxiga for chronic kidney disease

Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options


Sun Pharma acquires rights for Oxra, Oxramet and Oxraduo from AstraZeneca
News | May 28, 2021

Sun Pharma acquires rights for Oxra, Oxramet and Oxraduo from AstraZeneca

Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021


Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr
News | February 06, 2021

Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr

The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.